Callan Family Office LLC Has $2.45 Million Stake in Zoetis Inc. $ZTS

Key Points

• Callan Family Office LLC significantly increased its stake in Zoetis Inc. by 140.1% during the second quarter, now holding 15,717 shares valued at approximately $2.45 million.
• Several institutional investors have modified their positions in Zoetis, with 92.80% of the stock currently owned by hedge funds and other institutions.
• The quarterly earnings report indicated Zoetis beat expectations, reporting $1.76 earnings per share on revenue of $2.46 billion, leading to an annualized dividend yield of 1.4% with a quarterly dividend of $0.50 per share.

Callan Family Office LLC increased its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 140.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 15,717 shares of the company's stock after purchasing an additional 9,170 shares during the quarter. Callan Family Office LLC's holdings in Zoetis were worth $2,451,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Copperwynd Financial LLC boosted its stake in shares of Zoetis by 5.5% during the 2nd quarter. Copperwynd Financial LLC now owns 6,448 shares of the company's stock valued at $1,006,000 after buying an additional 339 shares during the period. Maryland State Retirement & Pension System boosted its position in Zoetis by 2.6% during the second quarter. Maryland State Retirement & Pension System now owns 21,690 shares of the company's stock valued at $3,383,000 after purchasing an additional 542 shares during the last quarter. First Merchants Corp boosted its position in Zoetis by 2.9% during the second quarter. First Merchants Corp now owns 26,547 shares of the company's stock valued at $4,140,000 after purchasing an additional 745 shares during the last quarter. Narwhal Capital Management purchased a new position in Zoetis in the second quarter valued at about $657,000. Finally, Citizens National Bank Trust Department raised its stake in shares of Zoetis by 19.8% during the 2nd quarter. Citizens National Bank Trust Department now owns 8,119 shares of the company's stock worth $1,266,000 after purchasing an additional 1,341 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ZTS shares. Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Weiss Ratings reissued a "hold (c-)" rating on shares of Zoetis in a research report on Wednesday. Argus restated a "buy" rating and set a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Piper Sandler upped their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Finally, Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and lowered their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Four equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $196.71.

Zoetis Stock Down 1.6%

Zoetis stock opened at $141.05 on Friday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a fifty-two week low of $139.34 and a fifty-two week high of $196.55. The firm has a fifty day moving average price of $149.24 and a two-hundred day moving average price of $154.41. The firm has a market cap of $62.51 billion, a price-to-earnings ratio of 24.28, a P/E/G ratio of 2.26 and a beta of 0.90.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same period last year, the business posted $1.56 earnings per share. The firm's revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. Zoetis's payout ratio is 34.42%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.